Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biotech Firms In China, India, Brazil Thriving; Time For Big Pharma To Step In?

This article was originally published in PharmAsia News

Executive Summary

By addressing local health challenges and leveraging cost-efficiency in research and development, biotech firms in emerging China, India, Brazil and South Africa (BRISA) are growing faster than ever. Global drug makers can benefit in these markets by sharing expertise and forming collaborations with these companies, say health researchers Rahim Razaie and Peter Singer at the Mclaughlin-Rotman Center for Global Health at the University of Toronto
Advertisement

Related Content

With More Vaccines For Low-Income Countries In Mind, Merck Signs JV With Wellcome Trust; India To Be Research And Manufacturing Hub
Sanofi Beats GSK To Buy Merieux Alliance's Stake In India's Shantha Biotech; Move Aimed At Stronger Vaccines Business In Emerging Markets
Sanofi Beats GSK To Buy Merieux Alliance's Stake In India's Shantha Biotech; Move Aimed At Stronger Vaccines Business In Emerging Markets
Advertisement
UsernamePublicRestriction

Register

SC075967

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel